GSK2245035, a TLR7 agonist, Does Not Increase Pregnancy Loss in Cynomolgus Monkeys

Autor: Posobiec, LM ^*, Hillegas, AE, Baker, A, Phadnis-Moghe, AS, Maier, CC, Stanislaus, DJ, Bray, M, Price, MA

Publikováno v: In Journal of Reproductive Immunology February 2021 143

No developmental toxicity observed with dolutegravir in rat whole embryo culture.

Autor: Posobiec LM; Department of Reproductive Toxicology, GlaxoSmithKline USA, Collegeville, Pennsylvania, USA., Chapman SP; Department of Reproductive Toxicology, GlaxoSmithKline USA, Collegeville, Pennsylvania, USA., Murzyn SF; Department of Reproductive Toxicology, GlaxoSmithKline USA, Collegeville, Pennsylvania, USA., Rendemonti JE; Department of Reproductive Toxicology, GlaxoSmithKline USA, Collegeville, Pennsylvania, USA., Stanislaus DJ; Department of Safety Assessment, GlaxoSmithKline USA, Philadelphia, Pennsylvania, USA., Romach EH; ViiV Healthcare US, Research Triangle Park, North Carolina, USA.

Publikováno v: Birth defects research [Birth Defects Res] 2021 Oct 01; Vol. 113 (16), pp. 1190-1197. Date of Electronic Publication: 2021 Aug 28.

Absence of developmental and reproductive toxicity in animals exposed to dolutegravir.

Autor: Stanislaus DJ; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Posobiec LM; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Laffan SB; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Solomon HM; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Ziejewski MK; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Romach EH; Non-Clinical Safety, Research & Development, Viiv Healthcare, Research Triangle Park, North Carolina.

Publikováno v: Birth defects research [Birth Defects Res] 2020 Feb 01; Vol. 112 (3), pp. 245-261. Date of Electronic Publication: 2019 Dec 20.

Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects.

Autor: Theunissen PT; a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.; b Medicines Evaluation Board , Utrecht , The Netherlands.; c Innovative Testing in Life Sciences and Chemistry, University of Applied Sciences Utrecht (HU) , Utrecht , The Netherlands., Beken S; d Federal Agency for Medicines and Health Products , Brussels , Belgium., Beyer BK; e Sanofi U.S. Inc. Bridgewater , NJ , USA., Breslin WJ; f Lilly Research Laboratories , Lilly Corporate Center , Indianapolis , IN , USA., Cappon GD; g Pfizer Worldwide Research & Development , Groton , CT , USA., Chen CL; h ILSI-Health and Environmental Sciences Institute , Washington , DC , USA., Chmielewski G; i Covance Laboratories Inc , Greenfield , IN , USA., De Schaepdrijver L; j Janssen R&D, Preclinical Development & Safety Beerse , Belgium., Enright B; k AbbVie Inc , North Chicago , IL , USA., Foreman JE; l ExxonMobil Biomedical Sciences, Inc , Annandale , NJ , USA., Harrouk W; m U.S. Food & Drug Administration , Silver Spring , MD , USA., Hew KW; n Takeda Pharmaceutical Company , Deerfield , IL , USA., Hoberman AM; o Charles-River Laboratories, Preclinical Services , Horsham , PA , USA., Hui JY; p Celgene Corporation , Summit , NJ , USA., Knudsen TB; q U.S. Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park , NC , USA., Laffan SB; r Safety Assessment, GlaxoSmithKline , King of Prussia , PA , USA., Makris SL; s U.S. Environmental Protection Agency, National Center for Environmental Assessment , Washington , DC , USA., Martin M; q U.S. Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park , NC , USA., McNerney ME; t Drug Safety Evaluation, Bristol-Myers Squibb , New Brunswick , NJ , USA., Siezen CL; b Medicines Evaluation Board , Utrecht , The Netherlands., Stanislaus DJ; r Safety Assessment, GlaxoSmithKline , King of Prussia , PA , USA., Stewart J; u Drug Safety & Metabolism, AstraZeneca , Macclesfield , UK., Thompson KE; t Drug Safety Evaluation, Bristol-Myers Squibb , New Brunswick , NJ , USA., Tornesi B; k AbbVie Inc , North Chicago , IL , USA., Van der Laan JW; a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.; b Medicines Evaluation Board , Utrecht , The Netherlands., Weinbauer GF; v Covance Preclinical Services GmbH , Muenster , Germany., Wood S; w Merck Research Laboratories , Upper Gwynedd , Pennsylvania , USA., Piersma AH; a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.; x Institute for Risk Assessment Sciences, Faculty of Veterinary Sciences , Utrecht University , Utrecht , The Netherlands.

Publikováno v: Critical reviews in toxicology [Crit Rev Toxicol] 2016 Nov; Vol. 46 (10), pp. 900-910. Date of Electronic Publication: 2016 Oct 19.

Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.

Autor: Borthwick AD; Department of Medicinal Chemistry, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK. alan.d.borthwick@drugmoldesign.com, Liddle J, Davies DE, Exall AM, Hamlett C, Hickey DM, Mason AM, Smith IE, Nerozzi F, Peace S, Pollard D, Sollis SL, Allen MJ, Woollard PM, Pullen MA, Westfall TD, Stanislaus DJ

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2012 Jan 26; Vol. 55 (2), pp. 783-96. Date of Electronic Publication: 2012 Jan 12.